Lexicon Pharma Details 2024 Executive Compensation
Ticker: LXRX · Form: DEF 14A · Filed: Apr 22, 2025
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: LXRP
TL;DR
Lexicon Pharma dropped its 2024 exec pay details. Check out Lonnel Coats & Michael Exton's equity awards.
AI Summary
Lexicon Pharmaceuticals, Inc. filed a DEF 14A on April 22, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to individuals such as Lonnel Coats and Michael S. Exton, with details on outstanding and unvested awards as of year-end 2024, 2023, and 2022.
Why It Matters
This filing provides transparency into how Lexicon Pharmaceuticals compensates its top executives, which can influence investor decisions and perceptions of the company's governance and financial health.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but the details on executive compensation can sometimes reveal potential issues or signal future strategic shifts.
Key Numbers
- 2024 — Fiscal Year (Executive compensation data reported for this year.)
- 2023 — Fiscal Year (Executive compensation data reported for this year.)
- 2022 — Fiscal Year (Executive compensation data reported for this year.)
Key Players & Entities
- LEXICON PHARMACEUTICALS, INC. (company) — Filer
- Lonnel Coats (person) — Executive
- Michael S. Exton Ph.D. (person) — Executive
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to disclose information regarding the solicitation of proxies for the company's annual meeting of stockholders, including details on executive compensation.
Who are the key individuals mentioned in relation to equity awards?
Lonnel Coats and Michael S. Exton are specifically mentioned in relation to equity awards granted and outstanding.
What time periods do the equity award details cover?
The filing provides details for equity awards granted, outstanding, and unvested for the fiscal years ending December 31, 2024, 2023, and 2022.
What is the company's standard industrial classification?
The company's standard industrial classification is Pharmaceutical Preparations [2834].
Where is Lexicon Pharmaceuticals, Inc. headquartered?
Lexicon Pharmaceuticals, Inc. is headquartered at 2445 Technology Forest Blvd., Suite 1100, The Woodlands, TX 77381.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 22, 2025 by Lonnel Coats regarding LEXICON PHARMACEUTICALS, INC. (LXRX).